Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options

Aristidis Veves, Miroslav Backonja, Rayaz Malik

Research output: Contribution to journalReview article

202 Citations (Scopus)

Abstract

Objective. To facilitate the clinician's understanding of the basis and treatment of painful diabetic neuropathy (PDN). Background. PDN is one of several clinical syndromes in patients with diabetic peripheral neuropathy (DPN) and presents a major challenge for optimal management. Methods. A systematic review of the literature was undertaken for articles specific to PDN, using Medline databases between 1966 and 2007. Results. The epidemiology of PDN has not been well established and on the basis of available data the prevalence of pain is 10% to 20% in patients with diabetes and from 40% to 50% in those with diabetic neuropathy. It has a significant impact on the quality of life and health care costs. Pathophysiologic mechanisms underlying PDN are similar to other neuropathic pain disorders and are broadly characterized as peripheral and central sensitization. The natural course of PDN is variable, with many patients experiencing spontaneous improvement and resolution of pain. Hyperglycemia-induced pathways result in nerve dysfunction and damage, which lead to hyperexcitable peripheral and central pathways of pain. Glycemic control may prevent or partially reverse DPN and modulate PDN. Quantifying neuropathic pain is difficult, especially for clinical trials, although this has improved recently with the development of neuropathic pain-specific tools, such as the Neuropathic Pain Questionnaire and the Neuropathic Pain Symptom Inventory. Current therapeutic options are limited to symptomatic treatment and are similar to other types of neuropathic pain. Conclusions. A better understanding of the peripheral and central mechanisms resulting in PDN is likely to promote the development of more targeted and effective treatment.

Original languageEnglish
Pages (from-to)660-674
Number of pages15
JournalPain Medicine
Volume9
Issue number6
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Diabetic Neuropathies
Natural History
Early Diagnosis
Epidemiology
Neuralgia
Therapeutics
Peripheral Nervous System Diseases
Pain
Central Nervous System Sensitization
Somatoform Disorders
Quality of Health Care
Hyperglycemia
Health Care Costs
Quality of Life
Clinical Trials
Databases

Keywords

  • Diabetic Neuropathy
  • Mechanisms
  • Neuropathic Pain
  • Pain Assessment
  • SymptomaticTherapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Painful diabetic neuropathy : Epidemiology, natural history, early diagnosis, and treatment options. / Veves, Aristidis; Backonja, Miroslav; Malik, Rayaz.

In: Pain Medicine, Vol. 9, No. 6, 2008, p. 660-674.

Research output: Contribution to journalReview article

@article{a54ce72766474078aa56fbaf7a8bb662,
title = "Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options",
abstract = "Objective. To facilitate the clinician's understanding of the basis and treatment of painful diabetic neuropathy (PDN). Background. PDN is one of several clinical syndromes in patients with diabetic peripheral neuropathy (DPN) and presents a major challenge for optimal management. Methods. A systematic review of the literature was undertaken for articles specific to PDN, using Medline databases between 1966 and 2007. Results. The epidemiology of PDN has not been well established and on the basis of available data the prevalence of pain is 10{\%} to 20{\%} in patients with diabetes and from 40{\%} to 50{\%} in those with diabetic neuropathy. It has a significant impact on the quality of life and health care costs. Pathophysiologic mechanisms underlying PDN are similar to other neuropathic pain disorders and are broadly characterized as peripheral and central sensitization. The natural course of PDN is variable, with many patients experiencing spontaneous improvement and resolution of pain. Hyperglycemia-induced pathways result in nerve dysfunction and damage, which lead to hyperexcitable peripheral and central pathways of pain. Glycemic control may prevent or partially reverse DPN and modulate PDN. Quantifying neuropathic pain is difficult, especially for clinical trials, although this has improved recently with the development of neuropathic pain-specific tools, such as the Neuropathic Pain Questionnaire and the Neuropathic Pain Symptom Inventory. Current therapeutic options are limited to symptomatic treatment and are similar to other types of neuropathic pain. Conclusions. A better understanding of the peripheral and central mechanisms resulting in PDN is likely to promote the development of more targeted and effective treatment.",
keywords = "Diabetic Neuropathy, Mechanisms, Neuropathic Pain, Pain Assessment, SymptomaticTherapy",
author = "Aristidis Veves and Miroslav Backonja and Rayaz Malik",
year = "2008",
doi = "10.1111/j.1526-4637.2007.00347.x",
language = "English",
volume = "9",
pages = "660--674",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Painful diabetic neuropathy

T2 - Epidemiology, natural history, early diagnosis, and treatment options

AU - Veves, Aristidis

AU - Backonja, Miroslav

AU - Malik, Rayaz

PY - 2008

Y1 - 2008

N2 - Objective. To facilitate the clinician's understanding of the basis and treatment of painful diabetic neuropathy (PDN). Background. PDN is one of several clinical syndromes in patients with diabetic peripheral neuropathy (DPN) and presents a major challenge for optimal management. Methods. A systematic review of the literature was undertaken for articles specific to PDN, using Medline databases between 1966 and 2007. Results. The epidemiology of PDN has not been well established and on the basis of available data the prevalence of pain is 10% to 20% in patients with diabetes and from 40% to 50% in those with diabetic neuropathy. It has a significant impact on the quality of life and health care costs. Pathophysiologic mechanisms underlying PDN are similar to other neuropathic pain disorders and are broadly characterized as peripheral and central sensitization. The natural course of PDN is variable, with many patients experiencing spontaneous improvement and resolution of pain. Hyperglycemia-induced pathways result in nerve dysfunction and damage, which lead to hyperexcitable peripheral and central pathways of pain. Glycemic control may prevent or partially reverse DPN and modulate PDN. Quantifying neuropathic pain is difficult, especially for clinical trials, although this has improved recently with the development of neuropathic pain-specific tools, such as the Neuropathic Pain Questionnaire and the Neuropathic Pain Symptom Inventory. Current therapeutic options are limited to symptomatic treatment and are similar to other types of neuropathic pain. Conclusions. A better understanding of the peripheral and central mechanisms resulting in PDN is likely to promote the development of more targeted and effective treatment.

AB - Objective. To facilitate the clinician's understanding of the basis and treatment of painful diabetic neuropathy (PDN). Background. PDN is one of several clinical syndromes in patients with diabetic peripheral neuropathy (DPN) and presents a major challenge for optimal management. Methods. A systematic review of the literature was undertaken for articles specific to PDN, using Medline databases between 1966 and 2007. Results. The epidemiology of PDN has not been well established and on the basis of available data the prevalence of pain is 10% to 20% in patients with diabetes and from 40% to 50% in those with diabetic neuropathy. It has a significant impact on the quality of life and health care costs. Pathophysiologic mechanisms underlying PDN are similar to other neuropathic pain disorders and are broadly characterized as peripheral and central sensitization. The natural course of PDN is variable, with many patients experiencing spontaneous improvement and resolution of pain. Hyperglycemia-induced pathways result in nerve dysfunction and damage, which lead to hyperexcitable peripheral and central pathways of pain. Glycemic control may prevent or partially reverse DPN and modulate PDN. Quantifying neuropathic pain is difficult, especially for clinical trials, although this has improved recently with the development of neuropathic pain-specific tools, such as the Neuropathic Pain Questionnaire and the Neuropathic Pain Symptom Inventory. Current therapeutic options are limited to symptomatic treatment and are similar to other types of neuropathic pain. Conclusions. A better understanding of the peripheral and central mechanisms resulting in PDN is likely to promote the development of more targeted and effective treatment.

KW - Diabetic Neuropathy

KW - Mechanisms

KW - Neuropathic Pain

KW - Pain Assessment

KW - SymptomaticTherapy

UR - http://www.scopus.com/inward/record.url?scp=50349092303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349092303&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2007.00347.x

DO - 10.1111/j.1526-4637.2007.00347.x

M3 - Review article

C2 - 18828198

AN - SCOPUS:50349092303

VL - 9

SP - 660

EP - 674

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 6

ER -